REGN Stock Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Regeneron Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$738.00 |
| 52 Week High | US$1,211.20 |
| 52 Week Low | US$735.95 |
| Beta | 0.14 |
| 11 Month Change | -21.61% |
| 3 Month Change | -38.45% |
| 1 Year Change | -7.55% |
| 33 Year Change | 14.71% |
| 5 Year Change | 100.00% |
| Change since IPO | 3,393.49% |
Recent News & Updates
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings
Nov 22
Regeneron: The Biotech Stock To Buy Now
Nov 19Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
Nov 04Recent updates
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings
Nov 22Regeneron: The Biotech Stock To Buy Now
Nov 19Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
Nov 04Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
Sep 25Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?
Sep 09Regeneron Stock: Valuation Now Demands More Growth
Aug 26Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price
Aug 22Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Aug 04Regeneron's Robust Pipeline And Financial Health Signal Continued Growth
Aug 02Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings
Jul 11Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why
Jun 08These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
May 21Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks
May 06Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing
Apr 30Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?
Apr 10Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
Mar 26Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings
Feb 16Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024
Feb 10Shareholder Returns
| REGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.5% | 2.4% | 2.2% |
| 1Y | -7.6% | 16.2% | 31.7% |
Return vs Industry: REGN underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: REGN underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| REGN volatility | |
|---|---|
| REGN Average Weekly Movement | 3.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: REGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: REGN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 14,165 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
Regeneron Pharmaceuticals, Inc. Fundamentals Summary
| REGN fundamental statistics | |
|---|---|
| Market cap | US$80.10b |
| Earnings (TTM) | US$4.65b |
| Revenue (TTM) | US$13.85b |
17.1x
P/E Ratio5.7x
P/S RatioIs REGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REGN income statement (TTM) | |
|---|---|
| Revenue | US$13.85b |
| Cost of Revenue | US$6.82b |
| Gross Profit | US$7.03b |
| Other Expenses | US$2.37b |
| Earnings | US$4.65b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 43.26 |
| Gross Margin | 50.75% |
| Net Profit Margin | 33.61% |
| Debt/Equity Ratio | 6.8% |
How did REGN perform over the long term?
See historical performance and comparison